Quantcast

Latest Gene therapy Stories

2014-04-29 09:52:38

New research looking at the success of clinical trials of stem cell therapy shows that trials appear to be more successful in studies where there are more discrepancies in the trial data. Researchers from Imperial College London conducted a meta-analysis of 49 randomised controlled trials of bone marrow stem cell therapy for heart disease. The study, published today in the British Medical Journal, identified and listed over 600 discrepancies within the trial reports. Discrepancies were...

2014-04-29 08:36:49

GULF SHORES, Ala., April 29, 2014 /PRNewswire/ -- If successful, Neuralgene's (http://www.neuralgene.com) PRCN-323 treatment could significantly change the prognosis for everyone with the rare genetic disorder known as adrenoleukodystrophy, or ALD. The biotech company has recently celebrated a series of early successes in the treatment of other neurological conditions like ALS (Lou Gehrig's disease). Founder and CEO Jason Williams, M.D., believes his team is on the path toward a cure...

Existing Cochlear Technology Used To Re-grow Auditory Nerves
2014-04-24 03:24:49

[ Watch The Video: Bionic Ear Delivers DNA To Regrow Auditory Nerve Cells ] University of New South Wales Researchers at UNSW Australia have for the first time used electrical pulses delivered from a cochlear implant to deliver gene therapy, thereby successfully regrowing auditory nerves. The research also heralds a possible new way of treating a range of neurological disorders, including Parkinson's disease, and psychiatric conditions such as depression through this novel way...

2014-04-22 12:30:18

- Proceeds will Further Strengthen Avalanche's Proprietary BioFactoryTM Platform and Advance Clinical Program in Wet Age-Related Macular Degeneration - MENLO PARK, Calif., April 22, 2014 /PRNewswire/ -- Avalanche Biotechnologies, Inc, a leader in the development of innovative gene therapies for serious eye diseases such as wet age-related macular degeneration (AMD), today announced the successful completion of a $55 million Series B financing. New investors were led by Venrock, and...

2014-04-08 12:30:51

DUBLIN, April 8, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/fv78n3/cardiovascular) has announced the addition of a new report "Cardiovascular Drug Delivery - Technologies, Markets and Companies" [http://www.researchandmarkets.com/research/fv78n3/cardiovascular ] to their offering. <start_newscom> (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Drug delivery to the cardiovascular system is different from...

2014-04-08 08:32:20

DUBLIN, April 8, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/492nrm/gene_therapy) has announced the addition of a new report "Gene Therapy - Technologies, Markets and Companies" [http://www.researchandmarkets.com/research/492nrm/gene_therapy ] to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Gene therapy can be broadly defined as the transfer of defined genetic material to specific target...

2014-04-08 08:32:18

DUBLIN, April 8, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/t2pjhw/personalized) has announced the addition of a new report "Personalized Medicine - Scientific and Commercial Aspects" [http://www.researchandmarkets.com/research/t2pjhw/personalized ] to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) The aim of personalized medicine or individualized treatment is to match the right drug to...

2014-04-07 16:08:27

The transfer, via a viral vector, of a normal copy of the gene deficient in patients, allowed to fully and very rapidly cure the heart disease in mice. These findings are published in Nature Medicine on 6 April, 2014. Friedreich's ataxia is a severe, rare hereditary disorder which combines progressive neuro-degeneration, impaired heart function and an increased risk of diabetes. The condition affects one in every 50,000 birth. There is currently no effective treatment for this disease. In...

2014-04-07 08:32:15

Members committed to the standardization of cell therapies, regenerative medicine drugs and other biologics. LARKSPUR, Calif., April 7, 2014 /PRNewswire/ -- Today BioCision, LLC, a leader in advanced temperature management technologies that standardize biomaterial handling, announced the establishment of the company's first advisory board. Lori Kunkel, MD, former chief medical officer at Pharmacyclics, Inc., will serve as chair of the board, and will be joined by Scott Burger, MD,...

2014-04-06 16:20:26

AAVLife aimed at advancing gene therapy for cardiomyopathy in Friedreich's ataxia to clinic DOWNINGTOWN, Pa., April 6, 2014 /PRNewswire-USNewswire/ -- The Friedreich's Ataxia Research Alliance (FARA) is pleased to recognize the ground-breaking gene-therapy research of FARA-funded scientist Dr. Hélène Puccio. In the current online issue of Nature Medicine, Dr. Puccio and her colleagues present significant results demonstrating that gene-replacement therapy using an adeno-associated...


Word of the Day
negawatt
  • A unit of saved energy.
Coined by Amory Lovins, chairman of the Rocky Mountain Institute as a contraction of negative watt on the model of similar compounds like megawatt.